Trial · NCT07473895
Topical 5% Spironolactone Gel Versus 0.1% Adapalene Gel for Acne Vulgaris: A Randomized Split-Face Study
NCT07473895, Phase 2, Not yet recruiting, Assiut University
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Topical 5% Spironolactone Gel Versus 0.1% Adapalene Gel for Acne Vulgaris: A Randomized Split-Face Study. Trials, record NCT07473895. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT07473895
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Topical 5% Spironolactone Gel Versus 0.1% Adapalene Gel for Acne Vulgaris: A Randomized Split-Face Study
- NCT number
- NCT07473895
- Status
- Not yet recruiting
- Phases
- Phase 2
- Enrollment
- 40 participants, estimated
- Lead sponsor
- Assiut University
- Conditions
- Acne Vulgaris
- Interventions
- Spironolactone 5% Topical Gel, Adapalene 0.1% Topical Gel
- First posted
- 2026-03-16
- Last updated
- 2026-03-17
Source ClinicalTrials.gov
Registered outcomes5
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Measure the Change in Acne Severity via Global Acne Grading System (GAGS) | Baseline and 8 weeks (end of treatment) | The GAGS is used to calculate acne severity separately for each half of the face. The face is divided into regions (forehead, cheeks, nose, chin) with assigned area factors. Each region is graded from 0 (no lesion) to 4 (nodule); the regional score is the product of the most severe lesion grade and the area factor |
| Secondary | Measure Comparative Change in Global Acne Grading System (GAGS) Score | 8 weeks | The difference in acne severity between the two treated sides of the face will be evaluated using the Global Acne Grading System (GAGS). The GAGS assesses acne severity by evaluating six anatomical locations (forehead, right cheek, left cheek, nose, chin, and chest/upper back). Each location is assigned a factor based on surface area and lesion type (comedones, papules, pustules, and nodules). The total score ranges from 0 to 44, where higher scores indicate more severe acne. The study will compare the reduction in GAGS scores between the facial side treated with topical 5% spironolactone nano-formulation gel and the side treated with topical 0.1% adapalene gel. |
| Secondary | Measure The Reduction in Total Lesion Count (TLC) | Baseline and 8 weeks | Sum of both inflammatory (papules, pustules) and non-inflammatory (open and closed comedones) lesions on each side of the face. |
| Secondary | Measure Change in Quality of Life Using the Cardiff Acne Disability Index (CADI) | Baseline and 8 weeks. | Quality of life will be assessed using the Cardiff Acne Disability Index (CADI), a validated patient-reported questionnaire designed to measure the psychological and social impact of acne. The CADI consists of 5 questions, each scored from 0 to 3, resulting in a total score ranging from 0 to 15. Higher scores indicate greater impairment in quality of life related to acne. The Arabic validated version of the CADI will be used in this study. Changes in CADI scores will be assessed from baseline to 8 weeks of treatment. |
| Secondary | Measure Patient Treatment Satisfaction Assessed by the Dermatology Treatment Satisfaction Questionnaire (DermSat-7) | 8 weeks | Patient satisfaction with treatment will be assessed using the Dermatology Treatment Satisfaction Questionnaire (DermSat-7). This patient-reported instrument contains 7 items evaluating treatment effectiveness, convenience, tolerability, and overall satisfaction. Each item is rated on a 5-point Likert scale, resulting in a total score range from 7 to 35. Higher scores indicate greater treatment satisfaction. Scores will be evaluated at the end of the treatment period. |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers7
The papers the trial lists on ClinicalTrials.gov.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT07473895
GET https://conductscience.org/api/trials/v1/NCT07473895/registered